MannKind Corporation has received recommendation from  the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) that their inhaled insulin product, AFREZZA, be granted marketing approval.  This is a huge step forward for MannKind and for the treatment of diabetes.

Forma designed a range of inhalers for MannKind based on the AFREZZA technology, enabling them to expand the technology into additional treatment areas.

We congratulate MannKind on achieving this milestone, and hope that marketing approval is granted so that diabetes patients world wide can gain the benefits of MannKind’s revolutionary technology.